Diabetes has a strong impact on the vascular system as well as the heart.  Excess glucose in the bloodstream can damage nerves and blood vessels, and over time, there can be a greater risk of stroke, heart disease, or peripheral arterial disease (PAD).

Myocardial Solutions’ software can potentially be used to assess the degree of damage by diabetes on the heart and the nature of the damage.

Relevant Papers

Korosoglou G, Humpert PM, Ahrens J, Oikonomou D, Osman NF, Gitsioudis G, Buss SJ, Steen H, Schnackenburg B, Bierhaus A, Nawroth PP and Katus HA. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging. 2012;35:804-11.

Oosterlinck W, Dresselaers T, Geldhof V, Nevelsteen I, Janssens S, Himmelreich U and Herijgers P. Diabetes mellitus and the metabolic syndrome do not abolish, but might reduce, the cardioprotective effect of ischemic postconditioningThe Journal of thoracic and cardiovascular surgery. 2013;145:1595–1602.

Contact Us

We work with Medical Research Centers, MRI Manufacturers,
Outpatient Imaging Centers and Physicians

Myocardial Solutions' technology has been used globally in over 70 major medical research centers and is established as the gold standard for strain measurement. The research has yielded over 250 articles in peer-reviewed journals (50 articles from Circulation and JACC alone) that validate CMR strain testing. MyoStrain’s predecessor software (HARP & VIRTUE) have 510(k) clearance and CE Mark certification.
MyoStrain has CE mark certification, and Myocardial Solutions is actively pursuing FDA 510(k) clearance for MyoStrain.